320 related articles for article (PubMed ID: 34762975)
1. Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies.
Qiu H; Yuan XY; Cabral T; Manguiat K; Robinson A; Wood H; Grant C; McQueen P; Westmacott G; Beniac DR; Lin L; Carpenter M; Kobasa D; Gräfenhan T
Antiviral Res; 2021 Dec; 196():105206. PubMed ID: 34762975
[TBL] [Abstract][Full Text] [Related]
2. Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency.
Mariotti S; Capocefalo A; Chiantore MV; Iacobino A; Teloni R; De Angelis ML; Gallinaro A; Pirillo MF; Borghi M; Canitano A; Michelini Z; Baggieri M; Marchi A; Bucci P; McKay PF; Acchioni C; Sandini S; Sgarbanti M; Tosini F; Di Virgilio A; Venturi G; Marino F; Esposito V; Di Bonito P; Magurano F; Cara A; Negri D; Nisini R
Front Immunol; 2021; 12():750386. PubMed ID: 34764961
[TBL] [Abstract][Full Text] [Related]
3. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
4. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
5. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
6. Antibody cocktail effective against variants of SARS-CoV-2.
Liang KH; Chiang PY; Ko SH; Chou YC; Lu RM; Lin HT; Chen WY; Lin YL; Tao MH; Jan JT; Wu HC
J Biomed Sci; 2021 Nov; 28(1):80. PubMed ID: 34814920
[TBL] [Abstract][Full Text] [Related]
7. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
8. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.
Chen RE; Winkler ES; Case JB; Aziati ID; Bricker TL; Joshi A; Darling TL; Ying B; Errico JM; Shrihari S; VanBlargan LA; Xie X; Gilchuk P; Zost SJ; Droit L; Liu Z; Stumpf S; Wang D; Handley SA; Stine WB; Shi PY; Davis-Gardner ME; Suthar MS; Knight MG; Andino R; Chiu CY; Ellebedy AH; Fremont DH; Whelan SPJ; Crowe JE; Purcell L; Corti D; Boon ACM; Diamond MS
Nature; 2021 Aug; 596(7870):103-108. PubMed ID: 34153975
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
[TBL] [Abstract][Full Text] [Related]
10. A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope.
VanBlargan LA; Adams LJ; Liu Z; Chen RE; Gilchuk P; Raju S; Smith BK; Zhao H; Case JB; Winkler ES; Whitener BM; Droit L; Aziati ID; Bricker TL; Joshi A; Shi PY; Creanga A; Pegu A; Handley SA; Wang D; Boon ACM; Crowe JE; Whelan SPJ; Fremont DH; Diamond MS
Immunity; 2021 Oct; 54(10):2399-2416.e6. PubMed ID: 34481543
[TBL] [Abstract][Full Text] [Related]
11. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
[TBL] [Abstract][Full Text] [Related]
12. The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines.
Murano K; Guo Y; Siomi H
Biochem Soc Trans; 2021 Dec; 49(6):2879-2890. PubMed ID: 34854887
[TBL] [Abstract][Full Text] [Related]
13. The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants.
Makdasi E; Zvi A; Alcalay R; Noy-Porat T; Peretz E; Mechaly A; Levy Y; Epstein E; Chitlaru T; Tennenhouse A; Aftalion M; Gur D; Paran N; Tamir H; Zimhony O; Weiss S; Mandelboim M; Mendelson E; Zuckerman N; Nemet I; Kliker L; Yitzhaki S; Shapira SC; Israely T; Fleishman SJ; Mazor O; Rosenfeld R
Cell Rep; 2021 Sep; 36(10):109679. PubMed ID: 34464610
[TBL] [Abstract][Full Text] [Related]
14. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
15. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
[TBL] [Abstract][Full Text] [Related]
16. IgV somatic mutation of human anti-SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity.
de Mattos Barbosa MG; Liu H; Huynh D; Shelley G; Keller ET; Emmer BT; Sherman E; Ginsburg D; Kennedy AA; Tai AW; Wobus C; Mirabeli C; Lanigan TM; Samaniego M; Meng W; Rosenfeld AM; Prak ETL; Platt JL; Cascalho M
JCI Insight; 2021 May; 6(9):. PubMed ID: 33769311
[TBL] [Abstract][Full Text] [Related]
17. Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19.
Chen J; Huang R; Nie Y; Wen X; Wu Y
Virol Sin; 2020 Dec; 35(6):713-724. PubMed ID: 33394351
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal Antibodies to S and N SARS-CoV-2 Proteins as Probes to Assess Structural and Antigenic Properties of Coronaviruses.
Kumar R; Christensen ND; Kaddis Maldonado RJ; Bewley MC; Ostman A; Sudol M; Chen EC; Buchkovich NW; Gontu A; Surendran Nair M; Nissly RH; Minns AM; Kapur V; Rossi R; Kuchipudi SV; Lindner SE; Parent LJ; Flanagan JM; Buchkovich NJ
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696329
[TBL] [Abstract][Full Text] [Related]
19. Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.
Xie J; Ding C; He J; Zhang Y; Ni S; Zhang X; Chen Q; Wang J; Huang L; He H; Li W; Ma H; Jin T; Zhang S; Gao Y
Front Immunol; 2021; 12():715464. PubMed ID: 34539645
[TBL] [Abstract][Full Text] [Related]
20. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.
Finkelstein MT; Mermelstein AG; Parker Miller E; Seth PC; Stancofski ED; Fera D
Viruses; 2021 Jan; 13(1):. PubMed ID: 33477902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]